A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group

Journal of Urology

Volumn 186, Issue 6, 2011, Pages 2158-2167

  Brausi, Maurizio ^a   Witjes, J Alfred ^b   Lamm, Donald ^c   Persad, Raj ^d   Palou, Joan ^e   Colombel, Marc ^f   Buckley, Roger ^g   Soloway, Mark ^h   Akaza, Hideyuki ⁱ   Böhle, Andreas ^j  

^a AUSL Modena   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f UNIVERSITÉ LYON 1   (France)

^g NORTH YORK GENERAL HOSPITAL   (Canada)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF TSUKUBA   (Japan)

^j HELIOS AGNES KARLL HOSPITAL   (Germany)

more..

Author keywords

administration; clinical protocols; drug therapy; intravesical; mycobacterium bovis; urinary bladder neoplasms

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; MITOMYCIN C;

BCG VACCINATION; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CONCEPTUAL FRAMEWORK; CONSENSUS; DISEASE COURSE; EVIDENCE BASED PRACTICE; HUMAN; MEDICAL LITERATURE; MEDICAL SOCIETY; NONMUSCLE INVASIVE BLADDER CANCER; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TRANSURETHRAL RESECTION; TREATMENT FAILURE;

ALGORITHMS; HUMANS; NEOPLASM INVASIVENESS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 80755172266     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.07.076     Document Type: Review

References (45)

1. M. Babjuk, W. Oosterlinck, and R. Sylvester European Association of Urology guidelines on TaT1 (non-muscle invasive) bladder cancer Update March 2009 2009 European Association of Urology Arnhem, the Netherlands http://www.uroweb.org/professional-resources/guidelines/online Accessed January 9, 2010
2. M.S. Soloway International consultation on bladder tumours Urology 66 2005 1
3. National Comprehensive Cancer Network Clinical practice guidelines in oncology: bladder cancer including upper tract tumors and urothelial carcinoma of the prostate Version 2 2010 NCCN Jenkintown, Pennsylvania www.nccn.org Accessed March 27, 2010
4. American Urological Association Guideline for the management of nonmuscle invasive bladder cancer (stages Ta,T1, and Tis): 2007 update 2007 American Urological Association Linthicum, Maryland www.auanet.org Accessed February 18, 2010
5. M.C. Hall, S.S. Chang, and G. Dalbagni Guidelines for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol 178 2007 2314
6. D. Lamm, M. Colombel, and R. Persad Clinical practice recommendations for the management of non-muscle invasive bladder cancer Eur Urol 7 suppl. 2008 651
7. W. Oosterlinck, E. Solsona, and H. Akaza Low-grade Ta (noninvasive) urothelial carcinoma of the bladder Urology 66 2005 75
8. A.M. Nieder, M. Brausi, and D. Lamm Management of stage T1 tumors of the bladder: International Consensus Panel Urology 66 2005 108
9. R.J. Sylvester, A. van derMeijden, and J.A. Witjes High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder Urology 66 2005 90
10. R. Persad, D. Lamm, and M. Brausi Current approaches to the management of non-muscle invasive bladder cancer: comparison of current guidelines and recommendations Eur Urol 7 suppl. 2008 637
11. H.W. Herr High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumor Semin Urol Oncol 15 1997 142
12. M. Brausi, L. Collette, and K. Kurth Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies Eur Urol 41 2002 523
13. K.T. Adiyat, D. Katkoori, and C.T. Soloway "Complete transurethral resection of bladder tumor": are the guidelines being followed? Urology 75 2010 365
14. M.C. Lee, H.S. Levin, and J.S. Jones The role of pathology review of transurethral bladder tumor resection specimens in the modern era J Urol 183 2010 921
15. R.J. Sylvester, W. Oosterlinck, and A.P. van derMeijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol 171 2004 2186
16. E. Kaasinen, E. Rintala, and P. Hellstrom Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma Eur Urol 42 2002 167
17. C. Bouffioux, K.H. Kurth, and A. Bono Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment J Urol 153 1995 934
18. I. Iborra Juan, J.V. Ricos Torrent, and J.L. MonrósLliso Results of a randomized, double blind prospective study of intravesical chemoprophylaxis with 2 drugs: adriamycin and mitomycin; and 2 ways of initiating the instillations: early and late Effect on recurrence and progression Arch Esp Urol 45 1992 1001
19. J.R. Oddens, A.P. van derMeijden, and R. Sylvester One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients Is it always safe? Eur Urol 46 2004 336
20. M.A. Brausi Challenging the EAU guidelines on non-muscle-invasive bladder cancer (NMIBC): single immediate instillation of chemotherapy after transurethral resection of NMIBC and chemotherapy versus bacillus Calmette-Guérin in treatment of intermediate-risk tumours Eur Urol 9 suppl. 2010 406
21. S. Gudjónsson, L. Adell, and F. Merdasa Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study Eur Urol 55 2009 773
22. A. Böhle, H. Leyh, and C. Frei Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study Eur Urol 56 2009 495
23. J. Dobruch, and H. Herr Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? BJU Int 104 2009 170
24. K. Hendricksen, W.P. Witjes, and J.G. Idema Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer Eur Urol 53 2008 984
25. I. Berrum-Svennung, T. Granfors, and S. Jahnson A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences J Urol 179 2008 101
26. T. Cai, G. Nesi, and G. Tinacci Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study J Urol 180 2008 110
27. E. Solsona, I. Iborra, and J.V. Ricós Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup J Urol 161 1999 1120
28. H. Zincke, D.C. Utz, and W.F. Taylor Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial J Urol 129 1983 505
29. H.W. Herr, S.M. Donat, and G. Dalbagni Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder J Urol 168 2002 978
30. W. Oosterlinck, K.H. Kurth, and F. Schröder A plea for cold biopsy, fulguration and immediate bladder instillation with Epirubicin in small superficial bladder tumors Data from the EORTC GU Group Study 30863 Eur Urol 23 1993 457
31. A. Pawinski, R. Sylvester, and K.H. Kurth A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer J Urol 156 1996 1934
32. D.L. Lamm, D.R. Riggs, and C.L. Traynelis Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder J Urol 153 1995 1444
33. R.J. Sylvester, W. Oosterlinck, and J.A. Witjes The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials Eur Urol 53 2008 709
34. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766
35. P.U. Malmström, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247
36. A.P. van derMeijden, R. Sylvester, and W. Oosterlinck EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ Eur Urol 48 2005 363
37. R.J. Sylvester, van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964
38. A. Böhle, and P.R. Bock Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression Urology 63 2004 682
39. A. Böhle, D. Jocham, and P.R. Bock Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 2003 90
40. B. Malavaud T1G3 bladder tumours: the case for radical cystectomy Eur Urol 45 2004 406
41. F.J. Bianco Jr, D. Justa, and D.J. Grignon Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy Urol Oncol 22 2004 290
42. A. Morales, D. Eidinger, and A.W. Bruce Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors J Urol 116 1976 180
43. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 2000 1124
44. H.W. Herr, and G. Dalbagni Defining bacillus Calmette-Guerin refractory superficial bladder tumors J Urol 169 2003 1706
45. H.W. Herr, and P.C. Sogani Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166 2001 1296